These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37961351)

  • 21. Understanding and targeting prostate cancer cell heterogeneity and plasticity.
    Tang DG
    Semin Cancer Biol; 2022 Jul; 82():68-93. PubMed ID: 34844845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
    Jacob A; Raj R; Allison DB; Myint ZW
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.
    Jillson LK; Yette GA; Laajala TD; Tilley WD; Costello JC; Cramer SD
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34208794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma.
    Cheng T; Zhou C; Bian S; Sobeck K; Liu Y
    Cancer Cell Int; 2024 Mar; 24(1):110. PubMed ID: 38528605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic Plasticity - Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer.
    Nanda JS; Koganti P; Perri G; Ellis L
    Crit Rev Oncog; 2022; 27(1):45-60. PubMed ID: 35993978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bipotent Progenitors Do Not Require Androgen Receptor for Luminal Specification during Prostate Organogenesis.
    Shibata M; Epsi NJ; Xuan S; Mitrofanova A; Shen MM
    Stem Cell Reports; 2020 Nov; 15(5):1026-1036. PubMed ID: 33176121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.
    Jindal R; Nanda A; Pillai M; Ware KE; Singh D; Sehgal M; Armstrong AJ; Somarelli JA; Jolly MK
    Comput Struct Biotechnol J; 2023; 21():1498-1509. PubMed ID: 36851919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.
    Che M; Chaturvedi A; Munro SA; Pitzen SP; Ling A; Zhang W; Mentzer J; Ku SY; Puca L; Zhu Y; Bergman AM; Severson TM; Forster C; Liu Y; Hildebrand J; Daniel M; Wang TY; Selth LA; Hickey T; Zoubeidi A; Gleave M; Bareja R; Sboner A; Tilley W; Carroll JS; Tan W; Kohli M; Yang R; Hsieh AC; Murugan P; Zwart W; Beltran H; Huang RS; Dehm SM
    Nat Commun; 2021 Nov; 12(1):6377. PubMed ID: 34737261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AR Signaling in Human Malignancies: Prostate Cancer and Beyond.
    Antonarakis ES
    Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29346310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TET2 directs mammary luminal cell differentiation and endocrine response.
    Kim MR; Wu MJ; Zhang Y; Yang JY; Chang CJ
    Nat Commun; 2020 Sep; 11(1):4642. PubMed ID: 32934200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
    J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
    Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
    Linder S; Hoogstraat M; Stelloo S; Eickhoff N; Schuurman K; de Barros H; Alkemade M; Bekers EM; Severson TM; Sanders J; Huang CF; Morova T; Altintas UB; Hoekman L; Kim Y; Baca SC; Sjöström M; Zaalberg A; Hintzen DC; de Jong J; Kluin RJC; de Rink I; Giambartolomei C; Seo JH; Pasaniuc B; Altelaar M; Medema RH; Feng FY; Zoubeidi A; Freedman ML; Wessels LFA; Butler LM; Lack NA; van der Poel H; Bergman AM; Zwart W
    Cancer Discov; 2022 Sep; 12(9):2074-2097. PubMed ID: 35754340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.
    Severson TM; Zhu Y; De Marzo AM; Jones T; Simons JW; Nelson WG; Yegnasubramanian S; Freedman ML; Wessels L; Bergman AM; Haffner MC; Zwart W
    Mol Oncol; 2021 Jul; 15(7):1942-1955. PubMed ID: 33576154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.
    Mardilovich K; Gabrielsen M; McGarry L; Orange C; Patel R; Shanks E; Edwards J; Olson MF
    Mol Cancer Ther; 2015 Jan; 14(1):246-58. PubMed ID: 25344584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
    Davies AH; Beltran H; Zoubeidi A
    Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
    Labrecque MP; Alumkal JJ; Coleman IM; Nelson PS; Morrissey C
    Endocr Relat Cancer; 2021 Jul; 28(8):T51-T66. PubMed ID: 33792558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.